12 results about "Peripheral blood lymphocyte" patented technology

The application discloses a use of Ejiao Qianggu oral liquid in regulating immunity, and particularly relates to an improving effect of the Ejiao Qianggu oral liquid on an immune system, which is realized by the following aspects. On one hand, the Ejiao Qianggu oral liquid promotes proliferation and transformation (mainly early T lymphocytes and part of B lymphocytes) and active functions of spleen lymphocytes; on the other hand, the Ejiao Qianggu oral liquid improves phagocytosis of macrophages. The Ejiao Qianggu oral liquid has the following characteristics: firstly, the Ejiao Qianggu oral liquid acts on early lymphocyte maturation, and has no significant effect on proliferation of peripheral blood lymphocytes; secondly, the Ejiao Qianggu oral liquid can significantly act on immune target organs, thymus and spleen tissues, and does not excessively stimulate the spleen, unlike positive drugs such as colony stimulating factor which can cause significant edema of the spleen; and thirdly, the Ejiao Qianggu oral liquid has a significant recovery effect on body weight, white blood cells, lymphocytes, red blood cells and hemoglobin in blood of patients with low immunity.

The invention provides a method for detecting insulin sensitivity, which comprises the following steps: (1) transfecting a cell to be detected by using a GLUT4myc cDNA plasmid: transfecting the cell to be detected by using the GLUT4myc cDNA plasmid, so that the cell stably expresses GLUT4myc; (2) measuring the endocytosis rate of the GLUT4myc: performing endocytosis stimulation to enable the GLUT4myc combined with the anti-myc antibody to be endocytosed, and regularly detecting the amount of the GLUT4myc combined with the anti-myc antibody remained on the surface of the cell; (3) measuring the GLUT4myc exocytosis rate: performing exocytosis stimulation to enable the GLUT4myc combined with the anti-myc antibody in the cell to exocytosis, and regularly detecting the translocation amount of the GLUT4myc combined with the anti-myc antibody in the cell to the surface of the cell; (4) calculating the difference value between the GLUT4myc exocytosis rate and the GLUT4myc endocytosis rate, and calculating the insulin sensitivity according to the difference value; the insulin sensitivity evaluation method has the beneficial effects that the insulin sensitivity is evaluated by detecting the exocytosis and endocytosis rates of fat cells, muscle cells or peripheral blood lymphocytes GLUT4, so that early-stage diabetic patients can be identified, and the pathogenesis of diabetes mellitus can be researched.

This invention discloses a T-cell training method based on tumor organ-on-a-chip. The method includes: preparing an organ-on-a-chip with a micropillar array and a biomimetic fishbone structure; introducing primary tumor cells from a patient into the chip, causing them to spontaneously form uniform three-dimensional tumor spheroids; dynamically pumping pre-activated peripheral blood lymphocytes from the same patient into the chip and co-culturing them with the tumor spheroids; collecting the co-cultured lymphocytes and repeating the co-culture process multiple times to obtain a lymphocyte population with enhanced anti-tumor activity. This invention utilizes organ-on-a-chip technology to highly simulate the dynamic tumor immune microenvironment in vivo. Through multiple cycles of "training," it effectively activates and expands tumor-specific T cells, avoiding immune exhaustion, and providing a highly efficient and controllable new platform for personalized immunotherapy of solid tumors.

The invention discloses a screening method and application of a shark-derived anti-idiotypic nano antibody, and belongs to the technical field of biological pharmacy and vaccines. The screening method comprises the following steps: immunizing adult shark by using a target pathogen specific antigen, collecting peripheral blood, separating lymphocytes, extracting RNA (Ribonucleic Acid), carrying out reverse transcription to synthesize cDNA (Complementary Deoxyribonucleic Acid), amplifying a nano antibody variable region fragment of a shark IgNAR (Immunoglobulin Nucleic Acid Receptor) gene, and constructing a phage display gene bank of which the storage capacity is greater than or equal to 1 * 10 < 8 > CFU and the recombination rate is greater than or equal to 85%; a variable region of a target pathogen specific antibody is taken as a target, specific bacteriophage is enriched through 3-4 rounds of gradient washing and elutriation (Tween-20 concentration and washing time are gradually improved), and the shark source anti-idiotypic nano antibody with high affinity and high purity (greater than or equal to 95%) is obtained by combining ELISA screening positive clone, gene sequencing de-weighting and SPR detection (combining dissociation constant KDlt, 1 * 10 <-7 > mol / L).

Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetically modified T cell receptors, and other genetic modifications, and uses of such expanded and / or modified PBLs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.

The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and / or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and / or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.

The invention discloses application of a detection reagent in malignant differentiation detection of Carbosi sarcoma, and belongs to the technical field of biological medicine. Aiming at the problem of insufficient specificity of a malignant differentiation marker of Carbosi sarcoma in the prior art, the invention provides application of a detection reagent in detection of the malignant differentiation of Carbosi sarcoma, and the detection reagent can simultaneously detect two biomarkers, namely CXCL12 and VWF, and is used for identifying endothelial cell malignant differentiation subgroups in tissue focuses of Carbosi sarcoma. By detecting the expression of CXCL12 and VWF in a tested sample, the endothelial cell malignant differentiation subgroup can be stably identified, and meanwhile, the expression level of CXCL12 can be used as an indicator of disease progression: the higher the expression level of CXCL12 is, the higher the lesion progression degree is, the higher the risk is, and the expression level is also positively correlated with the counting of peripheral blood lymphocytes. According to the invention, high-specificity recognition and standardized reading of the endothelial cell malignant differentiation subgroups are realized.

This invention discloses a shark-derived nanobody targeting the SARS-CoV-2 RBD protein and its applications. The nanobody's nucleotide sequence is shown in SEQ ID NO: 1, and its amino acid sequence is shown in SEQ ID NO: 5. Preparation involves immunizing a striped bamboo shark with the RBD protein, extracting total RNA from peripheral blood lymphocytes and reverse transcribing it into cDNA. The amplified VNAR fragment is then seamlessly ligated with amplified pR2 phage particles, transformed into TG1 competent cells, and a phage antibody library is constructed. SARS-CoV-2 RBD protein-specific nanobody sequences are screened from the library and recombinantly expressed to obtain the targeted shark-derived nanobody. The nanobody of this invention has a small molecular weight, allowing for the detection of the SARS-CoV-2 RBD antigen using paired nanobodies. It can be applied to immunoblotting, enzyme-linked immunosorbent assays (ELISA), and COVID-19 pharmaceutical applications related to the SARS-CoV-2 RBD protein.

This invention belongs to the field of nanobody technology, and relates to an anti-CD63 protein nanobody, its preparation method, and its application. The amino acid sequence of the nanobody is shown in SEQ ID NO.1. This invention utilizes CD63 protein as an immunogen to immunize alpacas, extracts total RNA from their peripheral blood lymphocytes, amplifies the VHH fragment via reverse transcription and two rounds of nested PCR, digests and ligates the VHH fragment with the pComb3XSS plasmid using enzymes, and transforms it into TG1 competent cells. Using phage display technology, after three rounds of screening, an anti-CD63 protein nanobody was successfully screened. This nanobody exhibits high specificity and good binding affinity, providing a new direction for the identification, enrichment, and purification of extracellular vesicles or exosomes, and for disease (such as tumor) diagnosis and targeted drug delivery.

The invention discloses a human mesenchymal stem cell preparation activated by specific immune pretreatment and application thereof, and the application is characterized in that human mesenchymal stem cells (hAMSCs) and autologous human peripheral blood lymphocytes are co-cultured and pretreated according to a specific ratio (such as 100: 1), and then are applied to a knee osteoarthritis model through intra-articular injection. The synergistic treatment effect which is obviously superior to that of the unpretreated hAMSCs can be generated; the Co-hAMSCs show a unique in-vivo action mode, the survival time of the Co-hAMSCs at the local part of the joint is shorter than that of common hAMSCs, but the Co-hAMSCs can quickly relieve pain in the early treatment stage, improve the joint function and lower local inflammation; the cartilage repair and regeneration can be more effectively promoted for a long time, and the specific expression is as follows: the cartilage histological score is obviously improved, the content of cartilage matrix glycosaminoglycans (especially middle and deep layers) is increased, and the repaired tissue is guided to be transformed to a hyaline cartilage sample phenotype with high expression of type II collagen and low expression of type I collagen, so that the cartilage repair and regeneration can be more effectively promoted. And inflammatory factor balance of local joints and the whole body can be synchronously adjusted.

The application discloses a single-domain antibody of decapod iridovirus 1 and a preparation method and application thereof, amino acid sequences of the single-domain antibody are shown in SEQ ID NO:1 or SEQ ID NO:2, and gene sequences are shown in SEQ ID NO:3 or SEQ ID NO:4; meanwhile, the application also provides a preparation method of the single-domain antibody of decapod iridovirus 1, adult healthy striped bonnet sharks are taken as immunization objects, and immunization is carried out by adopting DIV1 as an antigen; total RNA is extracted by separating peripheral blood lymphocytes of the immunized striped bonnet shark, and then the total RNA is reversely transcribed into cDNA; the cDNA is taken as a template, a vNAR fragment of the striped bonnet shark is amplified, and the vNAR fragment is connected with a carrier to construct a phage library; positive clones recognizing the DIV1 are selected from the phage library; an expression vector is constructed, the single-domain antibody of the DIV1 is induced to express, and finally the single-domain antibody of the decapod iridovirus 1 is obtained; and the single-domain antibody of the decapod iridovirus 1 is used for detecting the decapod iridovirus 1.

The invention relates to a PCOS prediction method and device based on an immune marker. The PCOS prediction method comprises the following steps: acquiring the immune marker of a patient; inputting the immune marker into the PCOS prediction model to obtain a PCOS probability value; under the condition that the PCOS probability value meets the first preset probability value, the probability that the patient suffers from the PCOS is high; and under the condition that the PCOS probability value does not meet the first preset probability value, the probability that the patient suffers from the PCOS is low. The method has the advantages that the PCOS disease probability is predicted through the subgroup phenotype information of the peripheral blood lymphocytes, the method is simple and rapid, and the prediction efficiency is improved; the PCOS immune typing probability is predicted through the subgroup phenotypic information of the peripheral blood lymphocytes, the method is simple and rapid, and the prediction efficiency is improved; whether the metformin is effective or not is predicted through the subgroup phenotype information of the peripheral blood lymphocytes, the method is simple and rapid, and the prediction efficiency is improved; whether the metformin is effective or not is predicted through the subgroup phenotype information and clinical information of the peripheral blood lymphocytes, the method is simple and rapid, and the prediction efficiency is improved.